Effects of Risperidone on Conduct and Disruptive Behavior Disorders in Children with Subaverage IQs

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 41, Issue 9, 2002, Pages 1026-1036

  Snyder, Richard ^a   Turgay, Atilla ^b   Aman, Michael ^c   Binder, Carin ^d   Fisman, Sandra ^e   Carroll, Allan ^f  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d Janssen Ortho Inc   (Canada)

^e London Health Sciences   (Canada)

^f GLENROSE REHABILITATION HOSPITAL   (Canada)

Author keywords

Cognitive effects; Conduct disorder; Disruptive behavior; Risperidone; Side effects; Standardized behavior ratings

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHLORAL HYDRATE; CHLORPROMAZINE; LITHIUM; LITHIUM CARBONATE; MELATONIN; NEUROLEPTIC AGENT; PLACEBO; PSYCHOSTIMULANT AGENT; RISPERIDONE; VALPROIC ACID;

AGGRESSION; AMENORRHEA; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CHILD; CHILD BEHAVIOR; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONDUCT DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CRYING; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; DYSPEPSIA; DYSTONIA; EPISTAXIS; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GALACTORRHEA; GYNECOMASTIA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; IMPULSIVENESS; INCREASED APPETITE; INTELLIGENCE QUOTIENT; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MENTAL DISEASE; MENTAL INSTABILITY; MUSCLE HYPERTONIA; PARKINSONISM; PERSONALITY DISORDER; PHARYNGITIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RHINITIS; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SYMPTOM; TARDIVE DYSKINESIA; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; VOMITING; WEIGHT GAIN; ANALYSIS OF VARIANCE; MENTAL DEFICIENCY; MULTICENTER STUDY; PRESCHOOL CHILD;

ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD, PRESCHOOL; CONDUCT DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL RETARDATION; RISPERIDONE; SINGLE-BLIND METHOD;

EID: 0036718693     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200209000-00002     Document Type: Article

References (41)

1. Allison DB, Mentore JL, Heo M et al. (1999), Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, The Risperidone Disruptive Behavior Study Group (2002), Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346
3. Aman MG, Madrid A (1999), Atypical antipsychotics in persons with developmental disabilities. Ment Retard Dev Disabil Res Rev 5:253-263
4. Aman MG, Singh NN, Stewart AW, Field CJ (1985a), The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491
5. Aman MG, Singh NN, Stewart AW, Field CJ (1985b), Psychometric characteristics of the Aberrant Behavior Checklist. Am J Ment Defic 89:492-502
6. Aman MG, Tassé MJ, Rojahn J, Hammer D (1996), The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil 17:41-57
7. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association
8. Benson BA, Aman MG (1999), Disruptive behavior disorders in children with mental retardation. In: Handbook of Disruptive Behavior Disorders, Quay HC, Hogan AE, eds. New York: Plenum, pp 559-578
9. Botteron K, Geller B (1999), Disorders, symptoms, and their pharmacology. In: Practitioner's Guide To Psychoactive Drugs, 2nd ed, Werry JS, Aman MG, eds. New York: Plenum, pp 183-209
10. Carman J, Peuskens J, Vangeneugden A (1995), Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Pychopharmacol 10:207-213
11. Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980), The Extrapyramidal Symptom Rating Scale (abstract). Can J Neurol Sci 7:233
12. Conner DF, Ozbayrak KR, Harrison RJ, Melloni Jr RH (1998), Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment. J Child Adolesc Psychopharmacol 8:27-38
13. Conners CK (1989), Manual for Conners' Rating Scales. North Tonawanda, NY: Multi-Health Systems
14. Delis DC, Kramer JH, Kaplan E, Ober BA (1998), California Verbal Learning Test, Children's Version, Manual. Orlando, FL: Psychological Corporation/Harcourt, Brace
15. Dickson RA, Glazer WM (1999), Hyperprolactinemia and male sexual dysfunction. J Clin Psychiatry 60:125
16. Dunn LM, Dunn LM (1981), Peabody Picture Vocabulary Test, Revised. Circle Pines, MN: American Guidance Service
17. Fava M (1997), Psychopharmacologic treatment of pathologic aggression. Pychiatr Clin North Am 20:427-451
18. Findling RL, Aman MG, Derivan A (2000a), Long-term safety and efficacy of risperidone in children with significant conduct problems and borderline IQ or mental retardation (poster). Presented at the 39th Annual American College of Neuropsychopharmacology meeting, San Juan, PR, December
19. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL (2000b), A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516
20. Fraser WI, Ruedrich S, Kerr M, Levitas A (1998), Beta-adrenergic blockers. In: Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook, Reiss S, Aman MG, eds. Columbus: Ohio State University Nisonger Center, pp 271-289; distributed by Brookes Publishers, Baltimore
21. Gadow KD, Sprafkin J (1994), Manual for the Stony Brook Child Symptom Inventories. Child Symptom Inventory: Parent Checklist. Child Symptom Inventory: Teacher Checklist. Stony Brook, NY: Checkmate Plus
22. Girouard N, Morin IN, Tassé MJ (1998), Étude de fidélité test-retest et accord inter-judges de la Grille D'Evaluation Comportementale Pour Enfants Nisonger (GECEN) [Test-retest and interjudge reliability study of the Grille of Comportemental Evaluation for Nisonger Children (GECEN)]. Rev Francoph Defic Intel 9:127-136
23. Hardan A, Johnson K, Johnson C, Hreczny B (1996), Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 35:1551-1556
24. Kim Y-K, Leen K, Lee M (1999), Risperidone and associated amenorrhea: a report of 5 cases. J Clin Psychiatry 60:315-317
25. Kleinberg DL, Davis JM, De Coster R, Van Baelen B, Brecher M (1999), Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19:57-61
26. National Institute of Mental Health (1985), CGI (Clinical Global Impression) scale. Psychopharmacol Bull 21:39-845
27. Popli A, Gupta S, Rangwani SR (1998), Risperidone-induced galactorrhea associated with a prolactin elevation. Ann Clin Psychiatry 10:31-33
28. Rojahn J, Matson JL, Lott D, Esbensen A, Smalls Y (2001), The Behavior Problems Inventory: an instrument for the assessment of self injury, stereotyped behavior and aggression/destruction in individuals with developmental disabilities. J Autism Dev Disord 31:577-588
29. Schaal D, Hackenberg T (1994), Toward a functional analysis of drug treatment for behavioral problems of people with developmental disabilities. Am J Ment Retard 99:123-140
30. Shiwach RS, Carmody TJ (1998), Prolactogenic effects of risperidone in male patients: a preliminary study. Acta Psychiatr Scand 98:81-83
31. Sparrow SS, Balla DA, Cicchetti DV (1984), Vineland Adaptive Behavior Scales. Circle Pines, MN: American Guidance Service
32. Stark JA, Menolascino FJ, Albarelli MH, Gray V (1988), Executive summary. In: Mental Retardation and Mental Health, Classification, Diagnosis, Treatment, Services, Stark JA, Menolascino FJ, Albarelli MH, Gray VC, eds. New York: Springer-Verlag
33. Tassé MJ, Aman MG, Hammer D, Rojahn J (1996), The Nisonger Child Behavior Rating Form: age and gender effects and norms. Res Dev Disabil 17:59-75
34. Tassé MJ, Lecavalier L (2000), Comparing parent and teacher ratings of social competence and problem behaviors. Am J Mem Retard 105:252-259
35. Tassé MJ, Morin IN, Girouard N (2000), Traduction et validation cannadienne-francaise du Nisonger Child Behavior Rating Form [Translation and validation of the French-Canadian Nisonger Child Behavior Rating Form]. Can Pychol/Psychol Can 44:116-123
36. Thorndike RL, Hagen EP, Sattler JM (1986), Guide for Administering and Scoring the Stanford-Binet Intelligence Scale, 4th ed. Chicago: Riverside Publishing
37. Vanden Borre R, Vermote R, Buttiens M et al. (1993), Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 87:167-171
38. Wechsler D (1983), Wechsler Preschool and Primary Scale of Intelligence, Revised. New York: Psychological Corporation/Harcourt, Brace
39. Wechsler D (1991), Manual for the Wechsler Intelligence Scale for Children, 3rd ed. San Antonio, TX: Psychological Corporation
40. Weller EB, Rowan A, Elia J, Weller RA (1999), Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. J Clin Psychiatry 60:5-11
41. Werry JS, Aman MG (1999), Anxiolytics, sedatives, and miscellaneous drugs. In: Practitioner's Guide to Psychoactive Drugs for Children and Adolescents, 2nd ed, Werry JS, Aman MG, eds. New York: Plenum, pp 433-469